CSIMarket Company Name, Ticker, Customers, else..
 
Nuo Therapeutics Inc   (NUOT)
Other Ticker:  
 
 
Price: $0.0000 $0.00 %
Day's High: 0.00 Week Perf:
Day's Low: $ 0.00 30 Day Perf:
Volume (M): 0 52 Wk High: $ 0.00
Volume (M$): $ 0 52 Wk Avg: $0.00
Open: $0.00 52 Wk Low: $0.00



 Market Capitalization (Millions $) -
 Shares Outstanding (Millions) 46
 Employees 25
 Revenues (TTM) (Millions $) 1
 Net Income (TTM) (Millions $) -2
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0

Nuo Therapeutics Inc
Nuo Therapeutics Inc is a healthcare company based in Pennsylvania, USA. They specialize in developing and commercializing medical technologies for the treatment of chronic wounds. Their flagship product, Aurix System, is a biologic wound care therapy that uses the patient's blood to deliver healing factors directly to the wound site. Nuo Therapeutics aims to provide innovative solutions for patients suffering from debilitating chronic wounds, enhancing their quality of life and promoting faster healing.


   Company Address: 8285 El Rio, Suite 190 Houston 77054 TX
   Company Phone Number: 396-4770   Stock Exchange / Ticker: NUOT


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ANIK      % 
CUTR      % 
ESTA      % 
IART      % 
MDXG      % 
SMTI      % 
• View Complete Report
   



Nuo Therapeutics Inc

NUOT Makes Waves with Impressive 283.923% Revenue Increase

NUOT, also known as Nuo Therapeutics Inc, recently announced a significant increase in revenue for the financial interval ending March 31, 2024. The company reported a robust revenue rise of 283.923%, amounting to $0.23 million. However, despite this positive news, the company still suffered a loss, amounting to $-0.02.
Comparing this financial interval to the prior reporting season, NUOT experienced a growing shortfall from $-0.01 per share. On the bright side, there was an improvement in revenue by 19.066% from $0.20 million.
Nuo Therapeutics Inc

Strong Third-Quarter Performance Positions Nuo Therapeutics Inc. as a Dominant Player in Medical Equipment & Supplies Industry

Nuo Therapeutics Inc: A Bullish Outlook for Future Growth
Nuo Therapeutics Inc, a leading Medical Equipment & Supplies company, recently reported third-quarter earnings that exceeded industry expectations. With a remarkable revenue rise of 507.166% year on year to $0.23 million, Nuo Therapeutics has demonstrated its robustness and resilience in the market. Although the company experienced a loss at $-0.02 per share, its strong revenue growth far outweighs this setback.
When compared to its industry peers, Nuo Therapeutics has clearly outperformed. The Medical Equipment & Supplies industry, as a whole, has averaged a revenue increase of just 4.80% during the same period. This significant gap in revenue growth showcases Nuo Therapeutics' ability to outshine its competitors and solidify its position as a market leader.
Nuo Therapeutics Inc

Nuo Therapeutics Sets the Stage for Explosive Growth with Revenue Surpassing $0.1 Million in Latest Fiscal Period



The stock market is known for its unpredictable nature, providing investors with opportunities for significant gains or losses. One company that recently made headlines is Nuo Therapeutics Inc. In this article, we will delve into the financial performance of this medical equipment and supplies company, uncovering interesting facts and shedding light on its outlook.
Revenue and Net Loss:
Nuo Therapeutics Inc reported a revenue of $0.118169 million during the fiscal period ending June 30, 2023. This signifies a positive growth trajectory for the company, as it showcases an improvement compared to the same reporting period a year ago, which saw a net loss of $-0.924 million. However, the recent fiscal year shows a net loss of $-0.872 million, indicating room for improvement.
Nuo Therapeutics Inc

Nuo Therapeutics Inc Outperforms Market Challenges with Improved Inventory Turnover Ratio in Q1 2023

Nuo Therapeutics Inc Inventory Turnover Ratio Improves in Q1 2023
Nuo Therapeutics Inc, a healthcare industry player, recently released its first-quarter report for 2023, which reveals improvements in its inventory turnover ratio. However, despite the increase, the ratio remained below the industry average due to challenging market conditions.
Nuo Therapeutics Inc's ability to sell and replace its inventory improved in the first quarter of 2023, with a sequential increase to 0.12. Although the increase is a positive sign, 341 companies in the healthcare sector had a higher inventory turnover ratio.






Nuo Therapeutics Inc's Segments





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com